Mei Pharma Inc SEC Filings

Lite Strategy, Inc. reported fiscal 2026 third quarter results, emphasizing its strategy of using Litecoin (LTC) as its primary treasury reserve asset and returning capital to shareholders. The company highlighted its active covered call options program, which has generated $0.7 million in net proceeds since October 2025.

Lite Strategy deployed covered call proceeds and 35,250 LTC to repurchase 1,629,136 shares under a broader $25 million share repurchase authorization, reflecting a focus on capital discipline and net asset value per share. Management also noted ongoing pre-clinical pharmaceutical programs as potential sources of non-dilutive capital.

The company framed recent Securities and Exchange Commission guidance indicating Litecoin exhibits digital commodity characteristics as a meaningful step toward regulatory clarity. Looking ahead, Lite Strategy plans to scale its options program, continue repurchases, and pursue strategic investments and partnerships that support broader Litecoin ecosystem growth.

Lite Strategy, Inc. reported a sharp increase in losses as it pivoted from drug development toward a Litecoin-focused treasury strategy for the quarter ended March 31, 2026. The company recorded a net loss of $23.7 million for the quarter and $58.1 million for the nine months, largely driven by a $46.0 million nine‑month loss from changes in the fair value of digital assets and related receivables.

Total assets rose to $57.8 million, dominated by $48.2 million of Litecoin-related digital assets and receivables, while cash and cash equivalents declined to $7.5 million. A $100.0 million PIPE financing in July 2025 funded the acquisition of LTC and new advisory and asset management warrants.

The company also authorized a $25.0 million share repurchase program and bought back about 1.6 million shares for $2.0 million during the nine months. Lite Strategy began writing covered call options on its LTC holdings to generate cash, exposing results to further digital asset price volatility under new fair value accounting.

Lite Strategy, Inc. reported a sharp increase in losses as it pivoted from drug development toward a Litecoin-focused treasury strategy for the quarter ended March 31, 2026. The company recorded a net loss of $23.7 million for the quarter and $58.1 million for the nine months, largely driven by a $46.0 million nine‑month loss from changes in the fair value of digital assets and related receivables.

Total assets rose to $57.8 million, dominated by $48.2 million of Litecoin-related digital assets and receivables, while cash and cash equivalents declined to $7.5 million. A $100.0 million PIPE financing in July 2025 funded the acquisition of LTC and new advisory and asset management warrants.

The company also authorized a $25.0 million share repurchase program and bought back about 1.6 million shares for $2.0 million during the nine months. Lite Strategy began writing covered call options on its LTC holdings to generate cash, exposing results to further digital asset price volatility under new fair value accounting.

Citadel-affiliated entities and Kenneth Griffin report beneficial ownership of Lite Strategy, Inc. common stock on an amended Schedule 13G. Griffin may be deemed to beneficially own 1,433,211 Shares, representing 3.9% of the outstanding common stock.

Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may each be deemed to beneficially own 1,085,626 Shares, or 3.0% of the class. Citadel Securities LLC, Citadel Securities Group LP and Citadel Securities GP LLC may each be deemed to beneficially own 347,585 Shares, or 0.9% of the class.

The ownership percentages are based on 36,769,677 Shares outstanding as of December 15, 2025. The reporting group certifies the securities were not acquired and are not held for the purpose of changing or influencing control of Lite Strategy.

Citadel-affiliated entities and Kenneth Griffin report beneficial ownership of Lite Strategy, Inc. common stock on an amended Schedule 13G. Griffin may be deemed to beneficially own 1,433,211 Shares, representing 3.9% of the outstanding common stock.

Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may each be deemed to beneficially own 1,085,626 Shares, or 3.0% of the class. Citadel Securities LLC, Citadel Securities Group LP and Citadel Securities GP LLC may each be deemed to beneficially own 347,585 Shares, or 0.9% of the class.

The ownership percentages are based on 36,769,677 Shares outstanding as of December 15, 2025. The reporting group certifies the securities were not acquired and are not held for the purpose of changing or influencing control of Lite Strategy.

Lite Strategy, Inc. reported fiscal 2026 second quarter results centered on a new, more active use of its Litecoin treasury and capital return strategy. The company began transforming its LTC holdings into a “productive reserve asset” by launching a covered call options program that generated nearly $600,000 in gross premiums in the quarter.

Management also used proceeds from these treasury operations to commence a $25 million stock repurchase program, aiming to practice disciplined capital allocation and address the discount to net asset value. As of December 31, 2025, Lite Strategy held $8.8 million in cash and cash equivalents and initiated pre-clinical R&D work on its drug candidate pipeline for potential out-licensing or sale opportunities.

Lite Strategy, Inc. reported fiscal 2026 second quarter results centered on a new, more active use of its Litecoin treasury and capital return strategy. The company began transforming its LTC holdings into a “productive reserve asset” by launching a covered call options program that generated nearly $600,000 in gross premiums in the quarter.

Management also used proceeds from these treasury operations to commence a $25 million stock repurchase program, aiming to practice disciplined capital allocation and address the discount to net asset value. As of December 31, 2025, Lite Strategy held $8.8 million in cash and cash equivalents and initiated pre-clinical R&D work on its drug candidate pipeline for potential out-licensing or sale opportunities.

Lite Strategy, Inc. reported a sharp increase in scale and a major shift in strategy for the quarter ended December 31, 2025. Total assets rose to $82.9 million from $18.3 million in June, driven mainly by $63.97 million of Litecoin holdings and $7.35 million of digital assets receivable tied to covered call option activity.

The company recorded a quarterly net loss of $30.8 million, compared with $2.7 million a year earlier, largely due to a $26.5 million decrease in the fair value of digital assets and related receivable remeasurement. Lite Strategy closed a $100.0 million PIPE in July 2025, issued common stock and pre-funded warrants, and then deployed $100.0 million to purchase Litecoin, adopting a Litecoin Treasury Strategy alongside its legacy oncology pipeline. It also authorized a $25.0 million share repurchase program and began buying back stock, repurchasing 137,541 shares for $0.2 million during the quarter, while ending with $8.8 million in cash and cash equivalents.

Lite Strategy, Inc. reported a sharp increase in scale and a major shift in strategy for the quarter ended December 31, 2025. Total assets rose to $82.9 million from $18.3 million in June, driven mainly by $63.97 million of Litecoin holdings and $7.35 million of digital assets receivable tied to covered call option activity.

The company recorded a quarterly net loss of $30.8 million, compared with $2.7 million a year earlier, largely due to a $26.5 million decrease in the fair value of digital assets and related receivable remeasurement. Lite Strategy closed a $100.0 million PIPE in July 2025, issued common stock and pre-funded warrants, and then deployed $100.0 million to purchase Litecoin, adopting a Litecoin Treasury Strategy alongside its legacy oncology pipeline. It also authorized a $25.0 million share repurchase program and began buying back stock, repurchasing 137,541 shares for $0.2 million during the quarter, while ending with $8.8 million in cash and cash equivalents.

Lite Strategy, Inc. reported that CEO, CFO and Secretary Justin J. File acquired a stock option covering 455,000 shares of common stock at an exercise price of $2.02 per share on February 12, 2026, as employment compensation.

The option grant was approved by the board on November 20, 2025, subject to shareholder approval of the 2026 Stock Omnibus Equity Compensation Plan, which shareholders approved on February 12, 2026. After this grant, File directly holds 635,000 derivative securities.

The option is 5.6% vested and exercisable as of February 12, 2026, with the remaining 94.4% vesting in 34 monthly installments beginning February 14, 2026, contingent on continued service.

Lite Strategy, Inc. reported that CEO, CFO and Secretary Justin J. File acquired a stock option covering 455,000 shares of common stock at an exercise price of $2.02 per share on February 12, 2026, as employment compensation.

The option grant was approved by the board on November 20, 2025, subject to shareholder approval of the 2026 Stock Omnibus Equity Compensation Plan, which shareholders approved on February 12, 2026. After this grant, File directly holds 635,000 derivative securities.

The option is 5.6% vested and exercisable as of February 12, 2026, with the remaining 94.4% vesting in 34 monthly installments beginning February 14, 2026, contingent on continued service.

Lite Strategy, Inc. reported results of its fiscal 2026 Annual Meeting held on February 12, 2026. Stockholders approved the 2026 Omnibus Equity Compensation Plan, which became effective upon approval and supports the company’s future stock-based incentive awards.

Approval of the 2026 plan also satisfied the contingency for previously disclosed Replacement Options granted to Mr. Justin J. File to purchase 455,000 shares of common stock. Stockholders elected Mr. File and Mr. Joshua Riezman as directors to terms running through fiscal 2029, approved an advisory vote on executive compensation, and ratified CBIZ CPAs as independent auditors for the fiscal year ending June 30, 2026.

At the meeting, 19,437,130 shares of common stock were represented by proxy out of 36,785,397 shares outstanding and entitled to vote, indicating substantial shareholder participation.

Lite Strategy, Inc. reported results of its fiscal 2026 Annual Meeting held on February 12, 2026. Stockholders approved the 2026 Omnibus Equity Compensation Plan, which became effective upon approval and supports the company’s future stock-based incentive awards.

Approval of the 2026 plan also satisfied the contingency for previously disclosed Replacement Options granted to Mr. Justin J. File to purchase 455,000 shares of common stock. Stockholders elected Mr. File and Mr. Joshua Riezman as directors to terms running through fiscal 2029, approved an advisory vote on executive compensation, and ratified CBIZ CPAs as independent auditors for the fiscal year ending June 30, 2026.

At the meeting, 19,437,130 shares of common stock were represented by proxy out of 36,785,397 shares outstanding and entitled to vote, indicating substantial shareholder participation.

Alexander Schornstein filed a Form 3 disclosing initial beneficial ownership in Lite Strategy, Inc. (MEIP). The filing reports ownership of 4,365,472 shares of Common Stock, of which 4,140,472 are held directly by Mr. Schornstein and 225,000 are held by Camino Capital GmbH, an entity of which he is the sole beneficial owner and holds sole voting power.

The filing indicates a reporting relationship to the issuer as a director and was dated as the event on 09/09/2025 with a signature dated 09/10/2025. No derivative securities or exercise terms were reported.

Alexander Schornstein reported beneficial ownership of 4,365,472 shares of MEI Pharma, Inc. common stock, representing 13.29% of the outstanding class. This holding includes 4,140,472 shares directly held by Mr. Schornstein and 225,000 shares held by Camino Capital GmbH, of which he is the sole beneficial owner with sole voting and dispositive power. The filing states these shares were purchased from August 11, 2025 through September 9, 2025 using the Reporting Person's personal funds and that ownership exceeded the 10% threshold on September 9, 2025.

The filer certifies the securities were not acquired to influence control of the issuer and is filing under the short-form Schedule 13G provision. The percentage is calculated using 32,837,743 shares outstanding as disclosed in the companys Form S-3 Amendment No. 1 dated August 26, 2025. The filing identifies the issuers principal executive office in San Diego, CA and provides the Reporting Persons address in Aachen, Germany.

Alexander Schornstein reported beneficial ownership of 4,365,472 shares of MEI Pharma, Inc. common stock, representing 13.29% of the outstanding class. This holding includes 4,140,472 shares directly held by Mr. Schornstein and 225,000 shares held by Camino Capital GmbH, of which he is the sole beneficial owner with sole voting and dispositive power. The filing states these shares were purchased from August 11, 2025 through September 9, 2025 using the Reporting Person's personal funds and that ownership exceeded the 10% threshold on September 9, 2025.

The filer certifies the securities were not acquired to influence control of the issuer and is filing under the short-form Schedule 13G provision. The percentage is calculated using 32,837,743 shares outstanding as disclosed in the companys Form S-3 Amendment No. 1 dated August 26, 2025. The filing identifies the issuers principal executive office in San Diego, CA and provides the Reporting Persons address in Aachen, Germany.

Alexander Schornstein reported beneficial ownership of 4,365,472 shares of MEI Pharma, Inc. common stock, representing 13.29% of the outstanding class. This holding includes 4,140,472 shares directly held by Mr. Schornstein and 225,000 shares held by Camino Capital GmbH, of which he is the sole beneficial owner with sole voting and dispositive power. The filing states these shares were purchased from August 11, 2025 through September 9, 2025 using the Reporting Person's personal funds and that ownership exceeded the 10% threshold on September 9, 2025.

The filer certifies the securities were not acquired to influence control of the issuer and is filing under the short-form Schedule 13G provision. The percentage is calculated using 32,837,743 shares outstanding as disclosed in the companys Form S-3 Amendment No. 1 dated August 26, 2025. The filing identifies the issuers principal executive office in San Diego, CA and provides the Reporting Persons address in Aachen, Germany.

MEI Pharma, Inc. has changed its corporate name to Lite Strategy, Inc., effective September 10, 2025, through an amendment to its certificate of incorporation filed in Delaware. Under Delaware law, this name change did not require a stockholder vote and does not alter the rights of existing stockholders.

Beginning September 11, 2025, the company’s common stock, par value $0.00000002 per share, will stop trading on the Nasdaq Capital Market under the ticker symbol “MEIP” and will start trading under the new ticker symbol “LITS.” The company also issued a news release on September 10, 2025, to announce the new name and ticker.